Top Markets
Coin of the day
Fusion Antibodies plc Fusion Antibodies plc

Fusion Antibodies plc

FAB
株式のランク #40225
Fusion Antibodies plc operates as a contract research organization (CRO),... Fusion Antibodies plc operates as a contract research organization (CRO), providing specialized services in the research, development, and manufacturing of recombinant proteins and antibodies. The company primarily focuses on solutions for oncology and infectious diseases, serving a global clientele across the United Kingdom, broader Europe, and North America. Its comprehensive suite of offerings encompasses monoclonal antibody discovery and advancement, antibody sequencing and engineering, and a distinct platform for antibody humanization and rational affinity maturation. Additionally, Fusion Antibodies provides recombinant protein expression, stable cell line development, and cGMP-compliant scale-up services. Clients span the pharmaceutical, biotechnology, and diagnostic sectors. Notably, the company maintains a collaborative partnership with Celonic AG. Established in 2000, Fusion Antibodies plc is headquartered in Belfast, United Kingdom.
株価
$0.1559364
最終同期: 2026-09-18
時価総額
$195.17K
変化(1日)
6.60%
変化(1年)
-30.91%
GB
取引 Fusion Antibodies plc (FAB)

カテゴリー

Fusion Antibodies plc(FAB)のP/S比率
September 2026 時点のP/S比率 TTM: 7.25
Fusion Antibodies plc の最新の財務報告および株価によると、現在のP/S比率(TTM)は 7.25 です。2024 年末時点でのP/S比率は 1.88 でした。
Fusion Antibodies plc の P/S 比率の履歴(2013 ~ 2026)
各年末時点のP/S比率
P/S比率 変化
2026 (TTM) 7.25 141.79%
2025 3.00 59.38%
2024 1.88 -45.47%
2023 3.45 6.43%
2022 3.24 -66.20%
2021 9.60 78.11%
2020 5.39 86.72%
2019 2.89 -54.34%
2018 6.32 -55.67%
2017 14.25 -22.61%
2016 18.42 -38.61%
2015 30.00 -20.48%
2014 37.73 -43.99%
2013 67.37 0.00%
同業他社のP/S比率
企業 P/S比率 P/S比率の差
10.44 43.99%
US
12.01 65.53%
NL
26.12 260.14%
US
3.76 -48.23%
AU
- -
CH